Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy
Launched by BOEHRINGER INGELHEIM · Nov 28, 2019
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • New users of Tio+Olo on the same date or of LABA, LAMA and ICS, either as a fixed-dose combination (LABA/LAMA/ICS) or free combination (LABA/ICS + LAMA, etc), on the same date between January 2013 and March 2019.
- • Diagnosis of COPD prior to first maintenance inhaler and age ≥ 40 years at index date
- Exclusion Criteria:
- • Less than one year of medical history information prior to the date of combined treatment initiation (index date)
- • Lung cancer, interstitial lung disease, or lung transplantation at any time prior to the index date
- • Asthma diagnosis within one year prior to the index date
About Boehringer Ingelheim
Boehringer Ingelheim is a global, research-driven pharmaceutical company dedicated to improving health and quality of life through innovative therapies. Established in 1885 and headquartered in Ingelheim, Germany, the company focuses on the development of prescription medicines in key therapeutic areas, including respiratory diseases, cardiovascular health, oncology, and immunology. Boehringer Ingelheim is committed to advancing medical science through rigorous clinical trials and collaborative research, striving to bring novel treatments to patients while upholding the highest standards of safety and efficacy. With a strong emphasis on sustainability and corporate responsibility, the company aims to make a meaningful impact on global health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Andover, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials